Immunovant is a pre-revenue biotech with quality below minimum standards and concentrated exposure to a single clinical program and a single device supplier, though analysts see roughly 23% upside to the price target and the risk/reward ratio is approximately 3.3-to-1 in favor of buyers at current levels.
Thesis pillars
- Dual Concentration Risk→Stable
- Negative Free Cash Flow→Stable
- Mixed Earnings Execution→Stable
- +1 more pillar — see the Why tab for full reasoning
Immunovant, Inc. (IMVT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $38.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 21%; Below-average business quality.
Immunovant is a clinical-stage immunology company developing IMVT-1402 (imeroprubart), an FcRn inhibitor, in six active indications including Graves' disease, D2T RA, myasthenia gravis, CIDP, Sjögren's disease, and CLE, after discontinuing batoclimab in April 2026 following... Read more
Sell if holding. Engine safety override at $38.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 21%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Immunovant, Inc.
About Immunovant, Inc.
IMVT-1402 (imeroprubart), Immunovant, Inc.'s sole pipeline asset following batoclimab's April 2026 discontinuation after two Phase 3 thyroid eye disease trials failed to meet their primary endpoints, is progressing through six active clinical programs spanning Graves' disease, D2T RA, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus erythematosus. Phase 1 healthy-adult data showed a 74% mean total IgG reduction after four weekly 600 mg subcutaneous doses of IMVT-1402. Immunovant has generated no product revenue, and top-line data for GD, MG, CIDP, and SjD are not expected until calendar year 2027.
Immunovant has no product revenue and relies on equity financing. All IMVT-1402 clinical trials use the YpsoMate autoinjector from Ypsomed AG, the intended commercial delivery device. The FcRn inhibitor class now includes established agents—efgartigimod (Argenx) and nipocalimab (Johnson & Johnson)—in MG and CIDP, creating patient-pool competition that the 10-K identifies as a material enrollment risk. The D2T RA trial is fully enrolled with 170 participants; Period 1 open-label data at Week 16 showed a 72.7% ACR20 response rate. In GD, two parallel registrational trials initiated in December 2024 (approximately 240 participants, 52 weeks) and June 2025 (approximately 210 participants, 26 weeks) each target euthyroid and ATD-free status as primary endpoint, with results planned for 2027. Manufacturing relies on third-party contract manufacturers.
Show full overview
With batoclimab discontinued and IMVT-1402 the sole remaining asset, Immunovant's value depends entirely on one molecule across six indications. The 10-K notes that except for D2T RA and CLE, first top-line data are not expected until sometime in calendar year 2027, contingent on fully enrolling and completing each trial on schedule. Enrollment in MG, CIDP, and GD may be slowed by the availability of efgartigimod, rozanolixizumab, and nipocalimab, and the 10-K warns that marketing authorization of these competitors may impair the ability to enroll patients into the company's trials. If two or more Phase 3 programs miss primary endpoints—mirroring the batoclimab TED experience—the company would face no remaining pipeline asset within its current portfolio.
See also: Healthcare · Biotechnology
From Immunovant, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-06Recent Developments — Immunovant, Inc.
Latest news
- NEWS Citigroup Maintains Buy on Immunovant, Raises Price Target to $61 — benzinga Jun 30, 2026 neutral
- NEWS CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga May 26, 2026 positive
- NEWS Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62 — benzinga May 26, 2026 positive
- NEWS Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30 — benzinga May 22, 2026 positive
- NEWS These Analysts Increase Their Forecasts On Immunovant After Q4 Results — benzinga May 21, 2026 positive
Generated 2026-07-06T06:40:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineIMVT-140210-K Item 1: 'we made a decision to discontinue further development of batoclimab across all indications to focus fully on IMVT-1402'
- HIGHSupplierYpsomed AG10-K Item 1: 'All studies evaluating IMVT-1402 are being conducted using the intended commercial drug formulation and delivery device, the YpsoMate® autoinjector developed by Ypsomed AG'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 21%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $36.07. Score 4.8/10, moderate confidence.
Take-profit target: $41.40 (+6.7% upside). Prior stop was $36.07. Stop-loss: $36.07.
Concentration risk — Pipeline: IMVT-1402; Concentration risk — Supplier: Ypsomed AG; Quality below floor (1.6 < 4.0).
Immunovant, Inc. trades at a P/E of N/A (forward -15.9). TrendMatrix value score: 6.0/10. Verdict: Sell.
24 analysts cover IMVT with a consensus score of 4.1/5. Average price target: $46.
What does Immunovant, Inc. do?Immunovant is a clinical-stage immunology company developing IMVT-1402 (imeroprubart), an FcRn inhibitor, in six active...
Immunovant is a clinical-stage immunology company developing IMVT-1402 (imeroprubart), an FcRn inhibitor, in six active indications including Graves' disease, D2T RA, myasthenia gravis, CIDP, Sjögren's disease, and CLE, after discontinuing batoclimab in April 2026 following Phase 3 TED trial failures. The company has no product revenue.